Severity of @entity3170 and XXXX association.

@entity1 @entity32 @entity2194 @entity66 @entity1596 @entity262 @entity726 @entity2883 @entity9465 @entity3170
OBJECTIVE: To analyze @entity1 characteristics and correlate between the site and severity of the @entity32 and ocular and/or @entity262 association in a cohort of @entity1 with @entity3170 . DESIGN: Retrospective case series. METHODS: Medical records of 100 @entity1 with @entity3170 were reviewed. Data were analyzed using a customized database software. RESULTS: The age range at presentation was 18 to 76 years (mean, 43; median, 44). Sixty-nine percent of the @entity1 were female. Thirty-two (32%) @entity1 had bilateral involvement. The @entity3170 was nodular in 23 eyes (16%). Half of the @entity1 had a concurrent @entity2194 . @entity262 was found in 36 @entity1 (36%). In two @entity1 , @entity3170 preceded a systemic @entity66 ( @entity2883 and @entity9465 ). Ocular complications included @entity1596 (11.4%), corneal involvement (15%), and @entity726 (7.8%). No significant correlation of the site and severity of @entity32 to the presence of associated @entity2194 was found. The mean follow-up was 16.5 months. Twenty-eight @entity1 experienced recurrence of @entity3170 during the follow-up. Half of the @entity1 required treatment with oral nonsteroidal anti-inflammatory drugs. CONCLUSIONS: @entity3170 is usually a benign, self-limited disease, but it should not be trivialized since it may be associated with @entity66 . A careful review of systems should be performed in all @entity1 presenting with @entity3170 , and this should be repeated at least annually during the follow-up. A thorough eye examination is obviously essential to detect and treat @entity2194 .
